ACRV ACRIVON THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, ACRIVON THERAPEUTICS INC reported revenue of n/a, net income of −$18.0M and diluted EPS of −$0.43; for the fiscal year ended December 2025 revenue was n/a.
ACRV annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$84.1M, net income −$77.9M (margin n/a), EPS −$2.02
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$89.2M, net income −$80.6M (margin n/a), EPS −$2.38
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$67.1M, net income −$60.4M (margin n/a), EPS −$2.74
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$32.7M, net income −$31.2M (margin n/a), EPS −$7.56
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$16.2M, net income −$16.2M (margin n/a), EPS −$9.32
ACRV quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$18.0M, EPS −$0.43
- Quarter ended Mar 31, 2026: revenue n/a, net income −$19.0M, EPS −$0.49
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$19.0M, EPS −$0.49
- Quarter ended Sep 30, 2025: revenue n/a, net income −$18.2M, EPS −$0.47
- Quarter ended Jun 30, 2025: revenue n/a, net income −$21.0M, EPS −$0.55
- Quarter ended Mar 31, 2025: revenue n/a, net income −$19.7M, EPS −$0.51
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$22.8M, EPS −$0.54
- Quarter ended Sep 30, 2024: revenue n/a, net income −$22.4M, EPS −$0.59
- Quarter ended Jun 30, 2024: revenue n/a, net income −$18.8M, EPS −$0.52
- Quarter ended Mar 31, 2024: revenue n/a, net income −$16.5M, EPS −$0.73
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$19.3M, EPS −$0.87
- Quarter ended Sep 30, 2023: revenue n/a, net income −$14.5M, EPS −$0.66
- Quarter ended Jun 30, 2023: revenue n/a, net income −$13.9M, EPS −$0.63
- Quarter ended Mar 31, 2023: revenue n/a, net income −$12.8M, EPS −$0.58
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$8.93M, EPS $4.98
- Quarter ended Sep 30, 2022: revenue n/a, net income −$9.20M, EPS −$5.17
- Quarter ended Jun 30, 2022: revenue n/a, net income −$5.82M, EPS −$3.29
- Quarter ended Mar 31, 2022: revenue n/a, net income −$7.22M, EPS −$4.08
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$4.34M, EPS n/a
- Quarter ended Sep 30, 2021: revenue n/a, net income −$2.44M, EPS −$1.38
ACRV cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$63.7M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$65.7M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$42.6M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$30.1M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$14.0M, share buybacks n/a
ACRV balance sheet
- Jun 30, 2026: cash $41.4M, total assets $99.1M, total liabilities $12.4M, shareholders' equity $86.7M
- Mar 31, 2026: cash $34.1M, total assets $108M, total liabilities $12.3M, shareholders' equity $95.5M
- Dec 31, 2025: cash $41.5M, total assets $130M, total liabilities $17.2M, shareholders' equity $113M
- Sep 30, 2025: cash $35.4M, total assets $145M, total liabilities $16.7M, shareholders' equity $129M
- Jun 30, 2025: cash $41.9M, total assets $159M, total liabilities $15.5M, shareholders' equity $143M
- Mar 31, 2025: cash $39.2M, total assets $176M, total liabilities $16.0M, shareholders' equity $160M
- Dec 31, 2024: cash $39.8M, total assets $197M, total liabilities $19.8M, shareholders' equity $177M
- Sep 30, 2024: cash $43.4M, total assets $215M, total liabilities $17.8M, shareholders' equity $197M
Is ACRV profitable?
No. ACRIVON THERAPEUTICS INC lost $74.2M over the last four quarters.
What is ACRV's EPS?
Diluted earnings per share over the last four quarters were −$1.88; −$0.43 in the latest quarter.